UCL's Freeline Therapeutics has priced its shares at $18 to raise nearly $159m through an IPO on the Nasdaq Global Select Market.
Freeline Therapeutics, a UK-based gene therapy developer based on University College London (UCL) research, has priced its shares at $18 and will raise almost $159m when it goes public today.
The company issued more than 8.8 million American Depositary Shares (ADSs), representing the same number of ordinary shares. Commercialisation firm Syncona invested $24.3m in the initial public offering and Freeline will trade on the Nasdaq Global Select Market using the ticker symbol FRLN.
Founded in 2015 by Syncona,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
